Five Prime Therapeutics, Inc. (NASDAQ:FPRX) shares were up 8% during mid-day trading on Monday . The stock traded as high as $37.01 and last traded at $36.55. Approximately 581,251 shares traded hands during trading, an increase of 135% from the average daily volume of 247,605 shares. The stock had previously closed at $33.83.
Several research analysts have recently issued reports on FPRX shares. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $55.00 price objective on shares of Five Prime Therapeutics in a research report on Thursday, June 8th. Finally, BidaskClub cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Five Prime Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $60.80.
The firm’s market capitalization is $996.83 million. The stock has a 50-day moving average of $30.13 and a 200-day moving average of $32.45.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The business had revenue of $7.80 million for the quarter, compared to analysts’ expectations of $8.32 million. During the same period in the previous year, the firm posted ($0.49) earnings per share. The firm’s revenue was down 16.1% compared to the same quarter last year. Equities analysts predict that Five Prime Therapeutics, Inc. will post ($5.16) earnings per share for the current year.
Large investors have recently bought and sold shares of the stock. Rockefeller Financial Services Inc. acquired a new position in Five Prime Therapeutics in the second quarter worth about $210,000. Alliancebernstein L.P. grew its stake in Five Prime Therapeutics by 9.2% in the first quarter. Alliancebernstein L.P. now owns 97,770 shares of the biotechnology company’s stock worth $3,534,000 after purchasing an additional 8,220 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Five Prime Therapeutics by 142.2% in the first quarter. Goldman Sachs Group Inc. now owns 217,462 shares of the biotechnology company’s stock worth $7,861,000 after purchasing an additional 127,693 shares in the last quarter. Marshall Wace North America L.P. grew its stake in Five Prime Therapeutics by 19.6% in the second quarter. Marshall Wace North America L.P. now owns 341,387 shares of the biotechnology company’s stock worth $10,241,000 after purchasing an additional 56,058 shares in the last quarter. Finally, AXA grew its stake in Five Prime Therapeutics by 77.0% in the first quarter. AXA now owns 15,400 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 6,700 shares in the last quarter. Institutional investors and hedge funds own 84.08% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Five Prime Therapeutics, Inc. (FPRX) Trading Up 8%” was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.thestockobserver.com/2017/09/13/five-prime-therapeutics-inc-fprx-trading-up-8.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.